ArticleFrontiers in immunology2024

The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab.

Weijie Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.